

Market Applicability													
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Revcovi (elapegedemase-ivlr)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Revcovi (elapegedemase-ivlr) intramuscular injection

APPROVAL CRITERIA

Requests for enzyme replacement therapy for Adenosine Deaminase Deficiency [Revcovi (elapegedemase-ivlr)] may be approved if the following criteria are met:

- I. Individual has a diagnosis of adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID);

AND

- II. Diagnosis is confirmed by any of the following:
 - A. Genetic testing revealing mutations in the ADA1 gene; **OR**
 - B. Positive newborn screening via T cell receptor excision circles (TRECs); **OR**
 - C. Characteristic laboratory findings such as decreased or absent ADA activity and increase in erythrocyte deoxyadenosine nucleotide (dATP/dAXP) levels;

AND

- III. Individual is using as a bridge to definitive therapy with hematopoietic stem cell transplantation (HSCT); **OR**
- IV. Individual is not a suitable candidate for HSCT (including but not limited to matched sibling or family donor not available); **OR**
- V. Individual has failed HSCT (Label; Kohn 2018).

Requests for Enzyme Replacement Therapy for Adenosine Deaminase Deficiency [Revcovi (elapegedemase-ivlr)] may **not** be approved for the following:

- I. Individual has severe thrombocytopenia.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability													
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 28, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2018;S0091-6749(18):31268-5.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0393-19